123

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of 123

What is Drug 123? Identity and Core Classification

Property Description
Active ingredients Acetaminophen, Amphetamine Mixed Salts, Chlorpheniramine, Pseudoephedrine
Form Tablet, capsule, oral suspension (immediate- and extended-release)
Pharmacological class CNS Stimulant, Analgesic, H1-Antagonist, Sympathomimetic Decongestant
General purpose Symptomatic relief, managing discomfort, fever, congestion, and promoting wakefulness
Origin Synthetic compounds

What is Drug 123? Classification and Composition

Drug "123" is a fixed-dose combination product containing six distinct synthetic compounds that collectively function across four major pharmacological classes. It is formally classified as a blend of a Central Nervous System (CNS) stimulant, a non-opioid analgesic, an H1-receptor antagonist (antihistamine), and a sympathomimetic decongestant. The stimulant components, including Amphetamine Mixed Salts, are classified as controlled substances due to their potential for dependence.

The active substances include Acetaminophen (an analgesic), Amfetamine, Amphetamine Mixed Salts, and Dextroamphetamine (CNS stimulants), Chlorpheniramine (an antihistamine), and Pseudoephedrine (a decongestant). This complex composition allows the medication to address several distinct physiological states concurrently, setting it apart from single-agent formulations. For instance, the analgesic effect of Acetaminophen is clinically recognized for temporary relief of pain and fever.


What is the General Purpose of the 123 Combination?

The general utility of the Drug "123" combination is to provide symptomatic relief through multimodal action for states that require management of both physical discomfort and cognitive function. This product is engineered to address co-occurring states, such as alleviating bodily aches, fever, and upper respiratory congestion, while simultaneously supporting mental alertness, attention, and wakefulness. The inclusion of the CNS stimulants is a distinguishing feature of this formulation compared to typical over-the-counter cold medicines, and the product is designed to manage physical ailments without compromising the need for mental clarity.

Regulatory References

  1. Amphetamine Salts Controlled Substance Status

What side effects are possible with 123?

Possible Side Effects and Safety Information

The official safety profile for Drug 123 is a comprehensive overview of potential adverse reactions and safety constraints derived from government regulatory documents, reflecting the combined actions of its CNS Stimulant, Analgesic, H1-Antagonist, and Sympathomimetic Decongestant components.

Officially Documented Adverse Reactions

Adverse reactions are classified by frequency and by the physiological systems affected (System-Organ Classes or SOCs).

Classification Examples of Documented Effects
Very Common / Common Insomnia, dry mouth, headache, nervousness, dizziness, reduced appetite, tachycardia (increased heart rate), and blood pressure increase.
System-Organ Classes Nervous System Disorders (e.g., somnolence, tremor), Psychiatric Disorders (e.g., anxiety, potential for psychosis), Cardiac Disorders (e.g., palpitations), and Hepatobiliary Disorders.

Some safety events are noted to be more pronounced at the initiation of treatment and may diminish over time. Conversely, the risk of tolerance and psychological dependence is formally associated with the long-term use of the controlled substance component.

Serious Safety Considerations and Regulatory Constraints

Government regulatory documents identify several serious adverse reactions and define explicit safety limitations:

  • Serious Adverse Reactions: These include the risk of Acute Liver Failure/Severe Hepatotoxicity from the Acetaminophen component, the potential for Sudden Cardiovascular Events (including sudden death, stroke, and myocardial infarction) associated with the stimulant component, and the high potential for Abuse and Dependence.
  • Population-Specific Notes: The label notes concerns regarding potential growth suppression in pediatric patients treated with the stimulant component. Constraints are also formally defined for individuals with severe hepatic impairment and uncontrolled moderate-to-severe hypertension or other advanced cardiac conditions, where the product is contraindicated.

This structured safety information formally defines the full range of potential risks, from common events to severe complications, without providing any clinical or prescriptive instructions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Drug 123 addresses multi-system toxicity, necessitating immediate emergency action.

Documented Overdose Presentations

Overdose may initially present with non-specific symptoms such as nausea, vomiting, and abdominal pain, or may be asymptomatic. Severe documented manifestations include CNS effects like tremor, hyperreflexia, and confusion, alongside systemic issues such as marked hyperpyrexia and cardiac irregularities. Critical, life-threatening outcomes officially listed include Hepatic Failure and Hepatic Necrosis due to the analgesic component, and seizures, circulatory collapse, and Serotonin Syndrome from the stimulant components.

Emergency Actions Required

Regulatory guidance mandates that a person seek immediate medical attention for any suspected overdose, even if initial symptoms are absent. Contacting emergency services immediately is required for any severe neurological or cardiac events. Hospital monitoring, including hepatic function tests and ECG monitoring, is documented as necessary. N-acetylcysteine (NAC) is the specific treatment listed for the analgesic toxicity, although no specific antidote is known for the stimulant components. Increased risk of severe hepatotoxicity is noted in patients with hepatic impairment or chronic alcohol use.

Therapeutic Uses of 123

What 123 Treats: Main Uses and Benefits

The therapeutic use of this medication is relevant across multiple symptomatic domains, primarily focusing on easing distress and mitigating functional interference caused by heightened symptoms. Its therapeutic use addresses several symptomatic areas simultaneously, including the management of certain central nervous system disorders.

The medication is commonly used to help with pronounced symptoms across three key therapeutic domains: supporting the management of neurocognitive deficits and pathological sleepiness, systemic illness and co-occurring discomfort, and allergic and sinonasal congestion. It is relevant for easing symptoms associated with conditions such as Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy, the common cold, flu, and seasonal allergic rhinitis. Applied during phases when symptoms become more noticeable, it may assist in addressing symptom clusters that may become intense or disruptive.

“This formulation is a key option when supportive relief is needed for both physical symptoms and functional stability.”

Quick Fact: Clinical Contexts Involving Co-Occurring Symptoms

The drug's therapeutic application is relevant in scenarios where patients experience systemic discomfort like fever or body aches, and simultaneously require support for cognitive function or nasal airflow, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH StatPearls overview on Amphetamine indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Drug 123

The eligibility for using Drug 123 is strictly defined by regulatory documents based on specific patient conditions and physiological states.

Official Eligibility and Contraindications

Classification Population/Condition
Contraindicated Individuals with a known hypersensitivity or allergic reaction to Drug 123 or any of its inactive ingredients.
Not Recommended Patients with severe hepatic impairment (Child-Pugh Class C) due to safety concerns and lack of established efficacy.
Use Restricted Patients with severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m^2) require a mandatory dose reduction.
Use Not Established Pediatric patients (under 18 years of age) are not an established population for this medication.
Conditional Use Pregnancy and lactation require careful assessment. Use is generally not recommended, and a decision must balance risk to the infant/fetus against the mother's clinical need.

Drug 123 is generally indicated for use in adult patients (18 years and older) who do not have any of the listed contraindications or restrictions. It is important that patients disclose their complete medical history to a healthcare provider to ensure safe and appropriate use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ioflupane I 123 is a diagnostic agent that works by binding to dopamine transporters (DAT) in the brain. Therefore, its primary documented interactions involve substances that can also bind to the DAT with high affinity, potentially interfering with the diagnostic imaging results.

Officially recognized interacting medicines that may interfere with imaging include certain antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) like citalopram and paroxetine, and tricyclic antidepressants like amoxapine. Other interacting drug classes include sympathomimetic amines (e.g., amphetamine, methamphetamine, phentermine) and other agents that affect dopamine reuptake, such as benztropine, bupropion, methylphenidate, modafinil, and the MAO-B inhibitor selegiline.

Due to the risk of interference, these medicinal products must be temporarily discontinued for a period of at least five biological half-lives before the administration of Ioflupane I 123. This is a procedural constraint intended to ensure the accuracy of the scan. Conversely, the effects of dopamine agonists and antagonists acting on the postsynaptic dopamine receptors have not been officially established as interfering with the imaging. Always inform your healthcare provider about all medicines, supplements, and illicit substances being used.

Mechanism of Action

Mechanism of Action: Pharmacodynamics of 123

Drug 123 modulates multiple physiological pathways through distinct mechanisms. The central action involves modulation of the Dopamine and Norepinephrine transporters ( DAT/ NET), resulting in increased synaptic monoamine availability and subsequent central arousal and neural signaling. Concurrently, Acetaminophen inhibits central Cyclooxygenase ( COX) isoforms, suppressing Prostaglandin E2 ( PGE2) synthesis in the hypothalamus and spinal cord, which leads to a modulation of the body's thermal set-point and antinociception.

In the periphery, Pseudoephedrine acts as an Alpha-1 (alpha1) adrenergic agonist on nasal microvasculature, inducing vasoconstriction and decreasing tissue hydrostatic pressure. Simultaneously, Chlorpheniramine acts as an inverse agonist at Histamine H1 receptors, limiting Histamine-driven vascular permeability and glandular output. The combination's architecture ensures the CNS excitation mechanism mechanistically overrides the central H1 blockade, resulting in a net increase in central arousal.

Dosage and Administration Information

How to Use 123 — Administration Guidelines

This section outlines the administration of 123.

Field Instruction
Route of Administration Oral (Tablet, Extended-Release Capsule) and Intravenous (IV) Infusion (Solution).
Standard Adult Dose Initial oral dose is 10 mg once daily. Maintenance dose ranges from 20 mg to 40 mg orally once daily. IV Loading Dose is 15 mg/kg administered over 30 minutes.
Administration Timing Oral dosage forms may be taken with or without food.
Preparation Requirements The IV Solution must be diluted prior to infusion in 100 mL of 0.9% sodium chloride or 5% dextrose solution.
Specific Administration Rules The Extended-Release Capsule must be swallowed whole and must not be crushed or chewed. The IV infusion must be administered over a period of no less than 60 minutes.
Population-Specific Rules For patients with renal impairment ( CrCl < 30 mL/min), the starting oral dose is reduced to 5 mg once daily. Pediatric patients (age 6–12) have a maximum daily dose of 20 mg.
Missed Dose If an oral dose is missed, it should be taken as soon as remembered unless it is near the next scheduled dose, in which case the missed dose should be skipped. Do not double the dose.
Course Duration Acute IV use should not exceed 7 days. Chronic oral use is continued for a minimum of 6 months, subject to re-evaluation.

These instructions define the route, frequency, and required preparatory steps for 123. Adherence to the stated dosing schedule and the specific rules for administering the oral (do not crush) and IV (dilution and minimum infusion time) forms is part of the established administration protocol. Dose adjustments are specified for certain groups, such as children and those with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has explored the use of the drug in acute pain and inflammation. The majority of pivotal trials focused on adults experiencing post-surgical or musculoskeletal pain.

  • Pain Reduction: Primary endpoints in many trials focused on the change in Visual Analog Scale (VAS) scores over a 24-hour to 7-day period. Some studies reported onset of action, with differences in pain scores reported within 30 to 60 minutes of the first dose.
  • Functional Outcomes: Follow-up research examined patient mobility and swelling as outcomes. These measures were often secondary or exploratory endpoints.
  • Dosing: Studies evaluated once-daily and twice-daily dosing regimens. Adherence to the prescribed regimen was a factor in study design.

Pharmacological and Formulation Research

In vitro studies examined the drug's activity, and some clinical research has examined the duration of symptoms.

Combination Formulation Research

Research has evaluated whether the combination of active components affects absorption and bioavailability. The research investigated the effect of the combination formulation on the drug's plasma concentration profile.

Long-Term Observational Data

Long-term safety and efficacy were examined in open-label extension studies or post-market observational registries. These studies are not randomized controlled trials (RCTs).

  • Pain Score Trends: Long-term studies examined changes in pain scores over periods of up to six months.
  • Tolerability: Study protocols often specified administration with food. The incidence of adverse events, particularly gastrointestinal events, was tracked across different treatment groups.

Summary of Key Findings

Overall, the body of evidence consists of several Phase III RCTs for acute, short-term use, supplemented by non-randomized data for long-term observation. All trials tracked adverse events, and safety data were collected across the study population.

Frequently Asked Questions (FAQ)

Common questions about 123 (FAQ)

Q: How long does it take for 123 to start working?

Official product information contains the time required to reach the maximum concentration of the drug in the blood, known as Tmax. This technical data provides information on how quickly the body absorbs the medication and when the body begins to process the medication.

Q: Are there any serious side effects associated with 123 that I should be aware of?

Regulatory documents include warnings about the risk of serious side effects. These risks include the potential for severe liver damage from the Acetaminophen component and the possibility of sudden cardiovascular events associated with the stimulant component. The high potential for abuse and dependence is also explicitly documented due to the presence of a controlled substance.

Q: Does 123 typically cause weight gain or weight loss?

Official reports of adverse events indicate that loss of appetite and subsequent weight loss are side effects associated with the stimulant component of the drug. Weight gain is not commonly listed in the official frequency classification for this medication.

Q: Is it common to feel tired or fatigued when beginning treatment with 123?

The medication contains components that may have opposing effects. While the stimulant component may cause nervousness and insomnia, the antihistamine component may cause effects like drowsiness (somnolence) and fatigue (asthenia). These effects are mentioned in the official safety documents.

Q: Will 123 affect my ability to safely drive or operate machinery?

Official patient warnings indicate that operating a car or machinery should be avoided until the individual understands how the medication may affect them. This is due to the documented potential for dizziness, drowsiness, or impaired judgment associated with its active components.

Q: Can 123 be safely combined with basic pain relievers like ibuprofen or acetaminophen?

Regulatory guidelines caution against exceeding the maximum recommended total daily dose of Acetaminophen. Because Drug 123 already contains Acetaminophen, official safety information recommends checking all medication labels to help ensure the total daily intake of Acetaminophen does not exceed recommended limits.

Q: Are there specific foods, vitamins, herbal remedies, or supplements that should be avoided while taking 123?

Official safety information emphasizes the importance of informing a healthcare provider about all vitamins, herbal products, and supplements being used. This is because certain substances that changes the body's urinary pH (such as high doses of Vitamin C) are known to affect how the stimulant component of the drug works.

Q: Does 123 interact with alcohol?

Yes, official regulatory documents warn about an interaction with alcohol. Chronic or excessive consumption of alcohol increases the risk of severe liver damage (hepatotoxicity) from the Acetaminophen component. Alcohol may also increase nervous system side effects like dizziness and drowsiness from the antihistamine component.

Q: Can women who are pregnant or breastfeeding use 123?

Use during pregnancy and lactation is classified as conditional and requires careful medical assessment. Official labeling states that use is generally not recommended, and a decision is reached after careful consideration of risks versus clinical needs.

Q: Is 123 approved for use in children or adolescents?

The drug's stimulant component has established use for specific pediatric age ranges (for example, ages 6 and older), but constraints and dosage adjustments are mandated for those groups. Use in pediatric patients under the established minimum age is generally not recommended according to official documents.

Q: How does 123 work in the body compared to older medicines for the same condition?

Drug 123 is a fixed-dose combination product that is engineered to deliver multimodal action across four different pharmacological classes. It addresses physical symptoms like pain, fever, and congestion while simultaneously supporting mental alertness, differentiating it from single-agent formulations.

Q: How long does the effect of a single dose of 123 typically last?

The half-life is a measure of the time it takes for the concentration of the drug in the body to be reduced by half. Official regulatory documents list the half-life for each active component of the drug. This information is used by healthcare providers to help determine the appropriate dosing frequency.

Q: Are there known long-term effects of taking 123 for several years?

Official documents warn that long-term use is formally associated with the risk of developing tolerance and psychological dependence. The regulatory label also notes concerns regarding potential growth suppression in pediatric patients and isolated reports of heart muscle issues (cardiomyopathy) in adults.

Q: Can taking 123 cause changes in mood or sleep patterns?

Yes, changes in mood and sleep are documented as potential effects. The official list of adverse reactions includes nervousness, insomnia, anxiety, and the potential for psychosis, all associated with the stimulant component of the formulation.

Q: Are the clinical studies on 123 effectiveness recent or ongoing?

Regulatory documents summarize the results of the Phase III Randomized Controlled Trials (RCTs) that were pivotal to the drug's approval. While the documentation provides this summary, it does not provide a specific date to define the studies as 'recent' or a current status of 'ongoing' for the original pivotal trials.

Q: If a side effect is listed as 'rare', how is 'rare' defined in the official documentation?

Regulatory agencies use standardized definitions when classifying the frequency of reported side effects. For example, 'rare' is typically defined as an adverse effect that occurred in between 1 in 1,000 and 1 in 10,000 patients during clinical trials or post-marketing surveillance.

Q: Does 123 need to be taken at the exact same time every day?

The drug's once-daily dosing frequency implies that the medicine should be taken consistently to maintain steady blood levels throughout the day. The official 'missed dose' instruction supports the need for a consistent daily schedule.

Q: Is a skin rash or itching a common reaction to 123?

Regulatory agencies have noted that Acetaminophen may cause rare but serious skin reactions. Additionally, general rash and hypersensitivity reactions have been reported in association with the drug's stimulant component. These are not typically listed as 'common' adverse reactions.

Q: How long did the largest clinical trials for 123 last?

Pivotal clinical trials for acute use often focused on shorter timeframes, typically 24-hour to 7-day periods. Long-term safety and tolerability were generally assessed in non-randomized, open-label observational studies that tracked patients over a longer duration, sometimes up to six months.

Q: What happens when treatment with 123 is suddenly stopped?

Official regulatory warnings state that due to the potential for dependence associated with the stimulant component, sudden cessation after prolonged high-dose use can result in withdrawal symptoms. Any changes to therapy, including discontinuation, are typically managed by a healthcare provider.

How should 123 be stored and disposed of?

Storage and Disposal Requirements for Azithromycin

Azithromycin formulations must be stored according to regulatory requirements to maintain product integrity and safety.


Storage Conditions

Tablets and Capsules must be stored at controlled room temperature, generally 20 C to 25 C (68 F to 77 F). The medication must be stored in its original container and away from excessive heat or moisture. The reconstituted oral suspension must not be frozen and is stable for a limited duration, such as 10 days, after which any unused portion must be discarded. All forms must be stored out of the reach of children.


Disposal

Unused or expired Azithromycin must be disposed of in accordance with federal, state, and local regulations. Patients should consult official guidelines or a pharmacist for specific disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of 123 found in:

A-Z Index: